In BRAF non-V600E mutant NSCLC, a study demonstrated that single-agent trametinib upregulates the AKT signaling pathway in this cell line, indicating resistance to single-agent MEK inhibitors (158). Here, AKT1 is linked to non-small cell lung carcinoma.